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OBJECTIVE: Few studies have assessed the effect of erec-
tile dysfunction (ED) treatment for psychological adjust-
ment. This study assessed the impact of ED therapy 
on psychological functioning at baseline and 12-month
follow-up using a battery of 10 standard psychological
measures previously used in ED research. METHODS:
Using an observational ED disease registry, clinical,
sociodemographic psychological, and HRQoL informa-
tion was collected at baseline prior to treatment and at 3,
6 and 12 months later. Psychological measures included
the Beck Depression Inventory, a Life Satisfaction ques-
tion, Marital Happiness item from the Locke Wallace
Marital Adjustment Test, Mental Health Index 5, SF 36
Vitality scale, SOS 10 (a measure of general psychologi-
cal health), State Trait Anxiety measure, and three MOS
subscales (Positive Affect, Belonging/Loneliness, Marital
Functioning). Only men who reported undergoing ED
treatment were included in this analysis sub-sample.
Patients were classiﬁed as treatment responders based on
improvements in IIEF scores. Group means at baseline
and 12-months and change between timepoints were
compared using t-tests. RESULTS: The cohort consisted
of 89 patients. 40 (45%) responded to therapy by the IIEF
criteria. At one year, responders reported better psycho-
logical functioning on 7 measures, with differences being
signiﬁcant (p < .05) on Life Satisfaction, Marital Happi-
ness, Positive Affect, and SOS 10. Responders reported
signiﬁcant improvement (p < .05) from baseline on 3 mea-
sures (Life Satisfaction, Positive Affect, and SOS 10) and
a signiﬁcant decline on one (SF 36 Vitality). CONCLU-
SIONS: Diagnosing and successfully treating ED has a
signiﬁcant impact on patient psychological functioning.
These results should encourage providers to actively diag-
nose and treat ED. Data from this study show that men
who fail primary therapy for ED should be offered sec-
ondary treatment, as many men in this study who failed
prior therapies still reported improved psychological
functioning when they began an effective secondary 
treatment.
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OBJECTIVE: Response to erectile dysfunction (ED) treat-
ment has typically been reported over a three-month
period in a number of pharmaceutical trials. Little is
known about the factors associated with response to
treatment over a longer period. The current study exam-
ines predictors associated with response to treatment at
12 months in a group of men enrolled in an ED disease
registry study. METHODS: Clinical information was col-
lected at baseline and HRQOL data was collected at base-
line, 3, 6, and 12-months. Eighty-nine men reported
receiving ED treatment while enrolled in the study and
completed the 12-month HRQOL questionnaire. Scores
on the IIEF erectile functioning scale at baseline and 
12-months were compared. Men who reported a 4-point
or greater improvement were considered treatment
responders (N = 40). Forty-nine men were classiﬁed as
non-responders. A multivariate logistic regression model
predicting treatment response at 12 months and control-
ling for age and baseline erectile functioning was speci-
ﬁed. RESULTS: Men who were treatment responders at
the 12-month follow-up were signiﬁcantly more likely at
baseline to have a partner who encourages sex (OR =
4.230, p = .0369), be unmarried (OR = 0.05, p = .0020),
report greater rigidity during sex (OR = 4.814, p = .0288),
and have more frequent morning erections (OR = 4.360,
p = .0432). CONCLUSIONS: Long-term response to ED
treatment is signiﬁcantly associated with baseline erectile
functioning (as measured by frequency of morning erec-
tions and penile rigidity during sex) and the supportive-
ness of a partner. Practitioners can use this information
to guide patient expectations for treatment outcomes and
to recommend other treatment if relationship concerns
are present.
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OBJECTIVE: To evaluate the psychometric properties 
of a new disease speciﬁc instrument, the female sexual
desire proﬁle (FSDP). METHODS: The FSDP is a self-
assessment questionnaire containing eight items that
address the occurrence of sexual desire and sexual recep-
tivity. The study enrolled a total of 174 patients with
hypoactive sexual desire disorder in 5 countries (Canada,
UK, Poland, Hungary and The Netherlands) randomized
to receive either active treatment or placebo. Patients
completed the FSDP on a daily basis during the baseline
and treatment periods. Standard psychometric analyses
were conducted. RESULTS: Conﬁrmatory factor analysis
was undertaken to provide evidence of a single construct
of desire in the FSDP. All FSDP questions loaded onto the
factor in excess of 0.4. Three questions had high loadings
in excess of 0.7 (items 2, 4 and 5). The FSDP had good
internal consistency, 0.72 for the baseline data and 0.86
for the treatment period. There was no indication of item
redundancy. The FSDP scores showed a moderate corre-
lation with desire domain of the Female Sexual Function
Index (FSFI) for the baseline period (0.39) and treatment
